|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have explored the basis for this heterogeneity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen receptor and two prostate carcinoma cell lines that do not contain detectable androgen receptor.
|
2386943 |
1990 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
(2) The c-erb B-2/neu protein was detected in both androgen-receptor-positive (LNCaP) and -negative (PC-3 and DU-145) human prostate cancer cell lines.
|
1353965 |
1992 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82.
|
1446639 |
1992 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor gene mutations in human prostate cancer.
|
1631125 |
1992 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor gene mutations in human prostate cancer.
|
8274409 |
1993 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
|
8145761 |
1993 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA.
|
8443809 |
1993 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is possible that analogous to an activated/altered growth factor receptor oncogene, codon 877 mutant AR with altered ligand binding may provide a selective growth advantage in the genesis of a subset of advanced prostate cancer.
|
8187068 |
1994 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.
|
7512791 |
1994 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer.
|
8292051 |
1994 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor alterations in prostatic carcinoma.
|
7971517 |
1994 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of the androgen receptor (AR) may be one of the mechanisms which contribute to progression of prostatic carcinoma to an androgen-independent stage.
|
7522959 |
1994 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
|
7511045 |
1994 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor gene mutations in prostate cancer are very rare and are reported only in exons 4-8.
|
7626493 |
1995 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer.
|
7728763 |
1995 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified a similar molecular mechanism in vivo for endocrine treatment failure in human prostate cancer which involves amplification of the androgen receptor (AR) gene.
|
7795646 |
1995 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have looked for androgen receptor mutations as a cause of male sexual ambiguity and as a possible reason for failure of androgen ablation therapy on prostatic carcinoma.
|
7770997 |
1995 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have previously reported that one of eight endocrine therapy-resistant prostate cancer cases showed AR gene mutation [Suzuki et al: J Steroid Biochem Mol Biol 46:759-765, 1993].
|
8827083 |
1996 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In other cases, altered androgen receptor activity due to its mutation or altered expression may lead to pathology such as recurrence of prostate cancer due to development of androgen independence allowing tumor cell proliferation under androgen deprivation.
|
9159212 |
1996 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Some AR mutations in prostate cancer show broadened ligand specificity, such that the transcription-factor activity of the AR can be stimulated not just by dihydrotestosterone (DHT) but also by estradiol and other androgen metabolites that have a low affinity for the AR.
|
8912473 |
1996 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence.
|
9816170 |
1996 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen receptor (AR) plays a central regulatory role in prostatic carcinoma and is a target of androgen ablation therapy.
|
8907206 |
1996 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A relatively high frequency of the Thr868Ala mutation (originally reported for the human prostate cancer cell line androgen receptor) is particularly found in metastatic lesions (bone metastases) of prostate cancer and can be considered as a hot spot.
|
8717468 |
1996 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we shown that androgen promoted up-regulation of AR mRNA in two androgen-independent human prostate cancer cell lines, PC3 and DU145, when each was transfected with a human AR cDNA.
|
8883219 |
1996 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current reports suggest the presence of androgen receptor (AR) defects in prostate cancer.
|
9444740 |
1997 |